APO Research
Talk to an analyst

APO RESEARCH · REPORT

Central Nervous System (CNS) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Central Nervous System (CNS) Therapeutics Market Outlook and Growth Opportunities 2026

29 December 2025198 pages

Choose your research edition.

Industry ResearchCentral Nervous System (CNS) Therapeutics Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Central Nervous System (CNS) Therapeutics Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Central Nervous System (CNS) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Central Nervous System (CNS) Therapeutics Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Central Nervous System (CNS) Therapeutics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Central Nervous System (CNS) Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Central Nervous System (CNS) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Central Nervous System (CNS) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Central Nervous System (CNS) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Central Nervous System (CNS) Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Central Nervous System (CNS) Therapeutics market include Biogen, UCB Pharma, Viatris, Eli Lilly, Roche, Merck & Co Inc, Novartis, Johnson and Johnson and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Central Nervous System (CNS) Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Central Nervous System (CNS) Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Central Nervous System (CNS) Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Central Nervous System (CNS) Therapeutics market.

Central Nervous System (CNS) Therapeutics Segment by Company

Biogen

UCB Pharma

Viatris

Eli Lilly

Roche

Merck & Co Inc

Novartis

Johnson and Johnson

Teva

Takeda

Central Nervous System (CNS) Therapeutics Segment by Type

CNS Trauma

Neurovascular Diseases

Neurodegenerative Diseases

Other

Central Nervous System (CNS) Therapeutics Segment by Application

Hospital

Online

Other

Central Nervous System (CNS) Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Central Nervous System (CNS) Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Central Nervous System (CNS) Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Central Nervous System (CNS) Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Central Nervous System (CNS) Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Central Nervous System (CNS) Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Central Nervous System (CNS) Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Central Nervous System (CNS) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Central Nervous System (CNS) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Central Nervous System (CNS) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Central Nervous System (CNS) Therapeutics industry.

Chapter 3: Detailed analysis of Central Nervous System (CNS) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Central Nervous System (CNS) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Central Nervous System (CNS) Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Central Nervous System (CNS) Therapeutics Industry Trends Table 2. Central Nervous System (CNS) Therapeutics Industry Drivers Table 3. Central Nervous System (CNS) Therapeutics Industry Opportunities and Challenges Table 4. Central Nervous System (CNS) Therapeutics Industry Restraints Table 5. Global Central Nervous System (CNS) Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Central Nervous System (CNS) Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Central Nervous System (CNS) Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Central Nervous System (CNS) Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Central Nervous System (CNS) Therapeutics Company, Product Type & Application Table 10. Global Central Nervous System (CNS) Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Central Nervous System (CNS) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of CNS Trauma Table 15. Significant Companies of Neurovascular Diseases Table 16. Significant Companies of Neurodegenerative Diseases Table 17. Significant Companies of Other Table 18. Global Central Nervous System (CNS) Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Central Nervous System (CNS) Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Central Nervous System (CNS) Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Central Nervous System (CNS) Therapeutics Sales Value Share by Type (2021-2026) Table 22. Global Central Nervous System (CNS) Therapeutics Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Table 24. Significant Companies of Online Table 25. Significant Companies of Other Table 26. Global Central Nervous System (CNS) Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Central Nervous System (CNS) Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Central Nervous System (CNS) Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Central Nervous System (CNS) Therapeutics Sales Value Share by Application (2021-2026) Table 30. Global Central Nervous System (CNS) Therapeutics Sales Value Share by Application (2027-2032) Table 31. Global Central Nervous System (CNS) Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Central Nervous System (CNS) Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Central Nervous System (CNS) Therapeutics Sales Value Share by Region (2021-2026) Table 34. Global Central Nervous System (CNS) Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Central Nervous System (CNS) Therapeutics Sales Value Share by Region (2027-2032) Table 36. Global Central Nervous System (CNS) Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Central Nervous System (CNS) Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Central Nervous System (CNS) Therapeutics Sales Value Market Share by Country (2021-2026) Table 39. Global Central Nervous System (CNS) Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Central Nervous System (CNS) Therapeutics Sales Value Market Share by Country (2027-2032) Table 41. Biogen Company Information Table 42. Biogen Business Overview Table 43. Biogen Central Nervous System (CNS) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Biogen Central Nervous System (CNS) Therapeutics Product Portfolio Table 45. Biogen Recent Development Table 46. UCB Pharma Company Information Table 47. UCB Pharma Business Overview Table 48. UCB Pharma Central Nervous System (CNS) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. UCB Pharma Central Nervous System (CNS) Therapeutics Product Portfolio Table 50. UCB Pharma Recent Development Table 51. Viatris Company Information Table 52. Viatris Business Overview Table 53. Viatris Central Nervous System (CNS) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Viatris Central Nervous System (CNS) Therapeutics Product Portfolio Table 55. Viatris Recent Development Table 56. Eli Lilly Company Information Table 57. Eli Lilly Business Overview Table 58. Eli Lilly Central Nervous System (CNS) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Eli Lilly Central Nervous System (CNS) Therapeutics Product Portfolio Table 60. Eli Lilly Recent Development Table 61. Roche Company Information Table 62. Roche Business Overview Table 63. Roche Central Nervous System (CNS) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Roche Central Nervous System (CNS) Therapeutics Product Portfolio Table 65. Roche Recent Development Table 66. Merck & Co Inc Company Information Table 67. Merck & Co Inc Business Overview Table 68. Merck & Co Inc Central Nervous System (CNS) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Merck & Co Inc Central Nervous System (CNS) Therapeutics Product Portfolio Table 70. Merck & Co Inc Recent Development Table 71. Novartis Company Information Table 72. Novartis Business Overview Table 73. Novartis Central Nervous System (CNS) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Novartis Central Nervous System (CNS) Therapeutics Product Portfolio Table 75. Novartis Recent Development Table 76. Johnson and Johnson Company Information Table 77. Johnson and Johnson Business Overview Table 78. Johnson and Johnson Central Nervous System (CNS) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Johnson and Johnson Central Nervous System (CNS) Therapeutics Product Portfolio Table 80. Johnson and Johnson Recent Development Table 81. Teva Company Information Table 82. Teva Business Overview Table 83. Teva Central Nervous System (CNS) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Teva Central Nervous System (CNS) Therapeutics Product Portfolio Table 85. Teva Recent Development Table 86. Takeda Company Information Table 87. Takeda Business Overview Table 88. Takeda Central Nervous System (CNS) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Takeda Central Nervous System (CNS) Therapeutics Product Portfolio Table 90. Takeda Recent Development Table 91. Research Programs/Design for This Report Table 92. Authors List of This Report Table 93. Secondary Sources Table 94. Primary Sources List of Figures Figure 1. Central Nervous System (CNS) Therapeutics Product Image Figure 2. Global Central Nervous System (CNS) Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Central Nervous System (CNS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Central Nervous System (CNS) Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. CNS Trauma Image Figure 8. Neurovascular Diseases Image Figure 9. Neurodegenerative Diseases Image Figure 10. Other Image Figure 11. Global Central Nervous System (CNS) Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Central Nervous System (CNS) Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Central Nervous System (CNS) Therapeutics Sales Value Share by Type (2021-2032) Figure 14. Hospital Image Figure 15. Online Image Figure 16. Other Image Figure 17. Global Central Nervous System (CNS) Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Central Nervous System (CNS) Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Central Nervous System (CNS) Therapeutics Sales Value Share by Application (2021-2032) Figure 20. Global Central Nervous System (CNS) Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Central Nervous System (CNS) Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Central Nervous System (CNS) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 23. North America Central Nervous System (CNS) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Central Nervous System (CNS) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Central Nervous System (CNS) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Central Nervous System (CNS) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Central Nervous System (CNS) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Central Nervous System (CNS) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 29. South America Central Nervous System (CNS) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Central Nervous System (CNS) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Central Nervous System (CNS) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • CNS Trauma
  • Neurovascular Diseases
  • Neurodegenerative Diseases
  • Other
Applications
  • Hospital
  • Online
  • Other
Companies covered
  • Biogen
  • UCB Pharma
  • Viatris
  • Eli Lilly
  • Roche
  • Merck & Co Inc
  • Novartis
  • Johnson and Johnson
  • Teva
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Central Nervous System (CNS) Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Central Nervous System (CNS) Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Central Nervous System (CNS) Therapeutics Market Dynamics
  1. 2.1 Central Nervous System (CNS) Therapeutics Industry Trends
  2. 2.2 Central Nervous System (CNS) Therapeutics Industry Drivers
  3. 2.3 Central Nervous System (CNS) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Central Nervous System (CNS) Therapeutics Industry Restraints
3 Central Nervous System (CNS) Therapeutics Market by Company
  1. 3.1 Global Central Nervous System (CNS) Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Central Nervous System (CNS) Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Central Nervous System (CNS) Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Central Nervous System (CNS) Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Central Nervous System (CNS) Therapeutics Company Product Type and Application
  6. 3.6 Global Central Nervous System (CNS) Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Central Nervous System (CNS) Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Central Nervous System (CNS) Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Central Nervous System (CNS) Therapeutics Market by Type
  1. 4.1 Central Nervous System (CNS) Therapeutics Type Introduction
  2. 4.1.1 CNS Trauma
  3. 4.1.2 Neurovascular Diseases
  4. 4.1.3 Neurodegenerative Diseases
  5. 4.1.4 Other
  6. 4.2 Global Central Nervous System (CNS) Therapeutics Sales Value by Type
  7. 4.2.1 Global Central Nervous System (CNS) Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Central Nervous System (CNS) Therapeutics Sales Value by Type (2021-2032)
  9. 4.2.3 Global Central Nervous System (CNS) Therapeutics Sales Value Share by Type (2021-2032)
5 Central Nervous System (CNS) Therapeutics Market by Application
  1. 5.1 Central Nervous System (CNS) Therapeutics Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Online
  4. 5.1.3 Other
  5. 5.2 Global Central Nervous System (CNS) Therapeutics Sales Value by Application
  6. 5.2.1 Global Central Nervous System (CNS) Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Central Nervous System (CNS) Therapeutics Sales Value by Application (2021-2032)
  8. 5.2.3 Global Central Nervous System (CNS) Therapeutics Sales Value Share by Application (2021-2032)
6 Central Nervous System (CNS) Therapeutics Regional Value Analysis
  1. 6.1 Global Central Nervous System (CNS) Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Central Nervous System (CNS) Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Central Nervous System (CNS) Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Central Nervous System (CNS) Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Central Nervous System (CNS) Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Central Nervous System (CNS) Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Central Nervous System (CNS) Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Central Nervous System (CNS) Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Central Nervous System (CNS) Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Central Nervous System (CNS) Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Central Nervous System (CNS) Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Central Nervous System (CNS) Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Central Nervous System (CNS) Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Central Nervous System (CNS) Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Central Nervous System (CNS) Therapeutics Country-level Value Analysis
  1. 7.1 Global Central Nervous System (CNS) Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Central Nervous System (CNS) Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Central Nervous System (CNS) Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Central Nervous System (CNS) Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Central Nervous System (CNS) Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Central Nervous System (CNS) Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Central Nervous System (CNS) Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Biogen
  2. 8.1.1 Biogen Company Information
  3. 8.1.2 Biogen Business Overview
  4. 8.1.3 Biogen Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Biogen Central Nervous System (CNS) Therapeutics Product Portfolio
  6. 8.1.5 Biogen Recent Developments
  7. 8.2 UCB Pharma
  8. 8.2.1 UCB Pharma Company Information
  9. 8.2.2 UCB Pharma Business Overview
  10. 8.2.3 UCB Pharma Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 UCB Pharma Central Nervous System (CNS) Therapeutics Product Portfolio
  12. 8.2.5 UCB Pharma Recent Developments
  13. 8.3 Viatris
  14. 8.3.1 Viatris Company Information
  15. 8.3.2 Viatris Business Overview
  16. 8.3.3 Viatris Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Viatris Central Nervous System (CNS) Therapeutics Product Portfolio
  18. 8.3.5 Viatris Recent Developments
  19. 8.4 Eli Lilly
  20. 8.4.1 Eli Lilly Company Information
  21. 8.4.2 Eli Lilly Business Overview
  22. 8.4.3 Eli Lilly Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly Central Nervous System (CNS) Therapeutics Product Portfolio
  24. 8.4.5 Eli Lilly Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Roche Central Nervous System (CNS) Therapeutics Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Merck & Co Inc
  32. 8.6.1 Merck & Co Inc Company Information
  33. 8.6.2 Merck & Co Inc Business Overview
  34. 8.6.3 Merck & Co Inc Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck & Co Inc Central Nervous System (CNS) Therapeutics Product Portfolio
  36. 8.6.5 Merck & Co Inc Recent Developments
  37. 8.7 Novartis
  38. 8.7.1 Novartis Company Information
  39. 8.7.2 Novartis Business Overview
  40. 8.7.3 Novartis Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novartis Central Nervous System (CNS) Therapeutics Product Portfolio
  42. 8.7.5 Novartis Recent Developments
  43. 8.8 Johnson and Johnson
  44. 8.8.1 Johnson and Johnson Company Information
  45. 8.8.2 Johnson and Johnson Business Overview
  46. 8.8.3 Johnson and Johnson Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Johnson and Johnson Central Nervous System (CNS) Therapeutics Product Portfolio
  48. 8.8.5 Johnson and Johnson Recent Developments
  49. 8.9 Teva
  50. 8.9.1 Teva Company Information
  51. 8.9.2 Teva Business Overview
  52. 8.9.3 Teva Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Teva Central Nervous System (CNS) Therapeutics Product Portfolio
  54. 8.9.5 Teva Recent Developments
  55. 8.10 Takeda
  56. 8.10.1 Takeda Company Information
  57. 8.10.2 Takeda Business Overview
  58. 8.10.3 Takeda Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Takeda Central Nervous System (CNS) Therapeutics Product Portfolio
  60. 8.10.5 Takeda Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst